






Oxalosis &
Hyperoxaluria
Foundation

STEPPING STONES TO A CURE

 **Location:** Virtual
 **Date:** October 5th, 2020
 **Time:** 10:00 AM – 3:00 PM EST

Externally-Led Patient Focused Drug Development Meeting on Primary Hyperoxaluria

9:45 – 10:00	Log On https://www.ohf.org/EL-PFDD-meeting
10:00 – 10:05	Welcome & Opening Remarks Kim Hollander, Executive Director, The Oxalosis & Hyperoxaluria Foundation
10:05 – 10:15	FDA PFDD Overview Dr. Aliza Thompson, Deputy Director of the Division of Cardiology and Nephrology in the Center for Drug Evaluation and Research at the Food and Drug Administration
10:15 – 10:30	Clinical Overview of Primary Hyperoxaluria Dr. Dawn Milliner, Professor of Pediatrics and Medicine, Mayo Clinic
10:30 – 10:40	Introduction & Meeting Overview James Valentine, Meeting Moderator: JD, MHS, Hyman, Phelps & McNamara

Morning Session: Living with Primary Hyperoxaluria - Symptoms and Daily Impact

10:40 – 10:45	Audience Demographic Polling
10:45 – 11:10	Panel 1: Patient & Caregiver Perspectives on Symptoms and Daily Impact
11:10 – 12:30	Audience Discussion and Remote Polling
12:30 – 1:00	Break

Afternoon Session: Current & Future Approaches to Treatment for Primary Hyperoxaluria

1:00 – 1:05	Journey For A Cure – Three Families Share Their Experiences
1:05 – 1:30	Panel 2: Patient & Caregiver Perspectives on Current & Future Treatments
1:30 – 2:50	Audience Discussion and Remote Polling
2:50 – 2:55	Meeting Summary Larry Bauer, RN, MA, Senior Regulatory Drug Expert, Hyman, Phelps & McNamara
2:55 – 3:00	Closing Remarks Kim Hollander, Executive Director, The Oxalosis & Hyperoxaluria Foundation